Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

clarkhealthcommunications

- PMLiVE

The Power of Partnership in Respiratory Care

In the fast-paced world of modern medicine, success is often measured by the volume of tests and the precision of data. However, as Dr. Doreen Addrizzo-Harris and Dr. Martina Flammer...

Medscape Education

- PMLiVE

UCB presentation highlights impacts of epilepsy on daily life

The data underlines the consequences of disrupted sleep for patients and caregivers

- PMLiVE

Inventiva appoints Axel-Sven Malkomes as Chief Financial Officer

Malkomes was most recently CFO at CureVac

Person_Swimming

Why clinical innovation doesn’t translate into real-life outcomes

We’ve made extraordinary progress in healthcare. However, outcomes depend on whether people can make treatment work in their lives.

Mednet

- PMLiVE

Strategies to enhance the provider and patient EAP experience

Expanded access programs (EAPs) play a multifaceted role in the drug development life cycle, serving as a critical bridge between clinical trials and commercial availability.

Uniphar

- PMLiVE

Biogen agrees $850m felzartamab rights deal with TJ Biopharma

The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases

- PMLiVE

myTomorrows partners with Rare Disease Research to boost rare disease referrals

The collaboration aims to improve patient identification and access to clinical trials

- PMLiVE

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

The treatment can be used to delay the onset of clinical type 1 diabetes

- PMLiVE

Helus Pharma appoints Ken Kramer as Senior VP, Medical Affairs

Kramer most recently served as VP and Head of Medical Neuroscience at Bristol Myers Squibb

- PMLiVE

Why the field is critical tonext-generation marketing

AI is fundamentally changing the way marketing operates omnichannel journeys, enabling true next-best communication

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

AI-powered launches on a limited budget: a playbook for emerging biopharma

Every AI decision must drive better outcomes and add greater value for clients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links